168 related articles for article (PubMed ID: 8780628)
1. Radiosensitizing nucleosides.
McGinn CJ; Shewach DS; Lawrence TS
J Natl Cancer Inst; 1996 Sep; 88(17):1193-203. PubMed ID: 8780628
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the use of radiosensitizing nucleosides.
McGinn CJ; Lawrence TS
Semin Radiat Oncol; 2001 Oct; 11(4):270-80. PubMed ID: 11677652
[TBL] [Abstract][Full Text] [Related]
3. Chemo-radiotherapy: radiosensitizing nucleoside analogues (review).
Gregoire V; Hittelman WN; Rosier JF; Milas L
Oncol Rep; 1999; 6(5):949-57. PubMed ID: 10425285
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis.
Grégoire V; Beauduin M; Bruniaux M; De Coster B; Octave Prignot M; Scalliet P
Int J Radiat Biol; 1998 May; 73(5):511-20. PubMed ID: 9652808
[TBL] [Abstract][Full Text] [Related]
5. The clinical rationale for S-phase radiosensitization in human tumors.
McGinn CJ; Kinsella TJ
Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
[TBL] [Abstract][Full Text] [Related]
6. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers.
Flanagan SA; Robinson BW; Krokosky CM; Shewach DS
Mol Cancer Ther; 2007 Jun; 6(6):1858-68. PubMed ID: 17575114
[TBL] [Abstract][Full Text] [Related]
7. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.
Ostruszka LJ; Shewach DS
Cancer Res; 2000 Nov; 60(21):6080-8. PubMed ID: 11085531
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and radiosensitization in human tumor cells.
Shewach DS; Lawrence TS
Invest New Drugs; 1996; 14(3):257-63. PubMed ID: 8958180
[TBL] [Abstract][Full Text] [Related]
9. The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.
Nitsche M; Christiansen H; Hermann RM; Lucke EM; Peters K; Rave-Frank M; Schmidberger H; Pradier O
Int J Radiat Biol; 2008 Aug; 84(8):643-57. PubMed ID: 18661380
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro.
Latz D; Fleckenstein K; Eble M; Blatter J; Wannenmacher M; Weber KJ
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):875-82. PubMed ID: 9652852
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Lawrence TS; Blackstock AW; McGinn C
Semin Radiat Oncol; 2003 Jan; 13(1):13-21. PubMed ID: 12520460
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization of human solid tumor cell lines with gemcitabine.
Shewach DS; Lawrence TS
Semin Oncol; 1996 Oct; 23(5 Suppl 10):65-71. PubMed ID: 8893885
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization with chemotherapeutic agents.
Caffo O
Lung Cancer; 2001 Dec; 34 Suppl 4():S81-90. PubMed ID: 11742709
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro.
Pauwels B; Korst AE; Pattyn GG; Lambrechts HA; Van Bockstaele DR; Vermeulen K; Lenjou M; de Pooter CM; Vermorken JB; Lardon F
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1075-83. PubMed ID: 14575839
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers.
Kinsella TJ
Semin Oncol; 1992 Jun; 19(3 Suppl 9):41-7. PubMed ID: 1641656
[TBL] [Abstract][Full Text] [Related]
16. Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.
Im MM; Flanagan SA; Ackroyd JJ; Shewach DS
Radiat Res; 2015 Jan; 183(1):114-23. PubMed ID: 25564718
[TBL] [Abstract][Full Text] [Related]
17. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Iwasaki H; Huang P; Keating MJ; Plunkett W
Blood; 1997 Jul; 90(1):270-8. PubMed ID: 9207462
[TBL] [Abstract][Full Text] [Related]
18. Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.
Wouters A; Pauwels B; Lambrechts HA; Pattyn GG; Ides J; Baay M; Meijnders P; Peeters M; Vermorken JB; Lardon F
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):558-66. PubMed ID: 21377279
[TBL] [Abstract][Full Text] [Related]
19. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine).
Lawrence TS; Chang EY; Hahn TM; Shewach DS
Clin Cancer Res; 1997 May; 3(5):777-82. PubMed ID: 9815749
[TBL] [Abstract][Full Text] [Related]
20. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.
Morgan MA; Parsels LA; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Nov; 14(21):6744-50. PubMed ID: 18980967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
